Skip to content

Other segment segments

Cygnus
$119.93M0.0%

Similar metrics at other companies

Qualcomm logo
QCOMQtl — Goodwill
$735M+0.1%
Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
Astronics logo
ATROTest Systems Segment — Goodwill
$21.64M0.0%
ABM Industries logo
ABMTechnical Solutions — Goodwill
$461.4M+2.6%
Stewart Information Services logo
STCTitle — Goodwill
$730.62M+0.3%
Trimble Inc. logo
TRMBT&L — Goodwill
$2.21B+3.6%

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$902.74M+204%
Enterprise value$1.01B+198%
P/S4.4×+3.2×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s trilink — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s trilink — goodwill?
Maravai LifeSciences Holdings, Inc. (MRVI) reported trilink — goodwill of $9.5M in Q4 2025.
What does trilink — goodwill mean?
Represents the intangible asset value recorded when the TriLink segment was acquired for a price exceeding the fair value of its identifiable net assets. This balance reflects the premium paid for expected synergies, market position, and future growth potential within the nucleic acid production market. Changes in this balance indicate strategic shifts or adjustments in the valuation of acquired business units.